Related Experiment Videos
Nitroflurbiprofen (NicOx)
1Istituto di Biochimica e Biochimica Clinica, Faculty of Medicine, Universita' Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168 Rome, Italy. r.scatena@uniserv.ccr.rm.cnr.it
Current Opinion in Investigational Drugs (London, England : 2000)
|June 19, 2004
Summary
Nitroflurbiprofen, a novel drug, is being investigated for urinary incontinence, Alzheimer's disease, and bone disorders. Clinical trials are progressing for various conditions, including dermatological applications.
Area of Science:
- Pharmacology and Drug Development
- Medicinal Chemistry
- Clinical Trials
Background:
- Nitroflurbiprofen is a nitrosylated analog of flurbiprofen.
- It is under development by NicOx for multiple therapeutic indications.
Purpose of the Study:
- To evaluate nitroflurbiprofen for urinary incontinence, Alzheimer's disease (AD), and bone resorption disorders.
- To assess a topical formulation for dermatological conditions like contact urticaria.
Main Methods:
- Phase IIa and II clinical trials for various indications including urinary incontinence, Paget's disease, and osteoporosis.
- Phase I trials for Alzheimer's disease.
- Ongoing development of a topical formulation for dermatological disorders.
Main Results:
- Nitroflurbiprofen has advanced into Phase IIa trials for urinary incontinence, Paget's disease, and osteoporosis.
- Phase II trials for topical nitroflurbiprofen in contact urticaria were underway.
- Phase I trials for Alzheimer's disease commenced.
Conclusions:
- Nitroflurbiprofen demonstrates potential across a range of conditions, from urological and neurological disorders to bone diseases and dermatological applications.
- Ongoing clinical trials indicate continued development and investigation into its therapeutic efficacy.